Stammdaten
Natera, Inc., ein Diagnostikunternehmen, entwickelt und vermarktet molekulare Testdienste weltweit. Das Unternehmen bietet Panorama, einen nicht-invasiven Pränataltest zur Prüfung auf chromosomale Abnormitäten eines Fötus durch einen Blutabstrich der Mutter, ebenso wie Zwillingsschwangerschaften bezüglich Zygosität; Vistara, einen Screening-Test für Einzelgen-Mutationen zur Identifikation von Einzelgen-Störungen; Horizon-Träger-Screening zur Bestimmung des Trägerstatus für verschiedene genetische Erkrankungen; und Spectrum zur Identifikation von chromosomalen Anomalien oder vererbten genetischen Erkrankungen während eines In-vitro-Befruchtungszyklus. Das Unternehmen bietet auch Anora-Fehlgeburtstest-Produkte zur Analyse fetaler Chromosomen zur Bestimmung der Ursache einer Fehlgeburt; und nicht-invasive Vaterschaftstest-Produkte zur Bestimmung der Vaterschaft mittels Schwangerschaft durch einen Blutabstrich von der schwangeren Mutter und dem mutmaßlichen Vater. Zusätzlich bietet es Constellation an, ein cloudbasiertes Softwareprodukt, das Laborkundenlabore befähigt, über die Cloud auf die Algorithmen und Bioinformatik des Unternehmens zuzugreifen, um Tests zu validieren und einzuführen; Signatera, eine zirkulierende Tumor-DNA-Technologie, die auf einen generischen Satz von Mutationen unabhängig vom Tumor eines Individuums prüft; und Prospera zur Bewertung der Transplantatablehnung. Das Unternehmen bietet Produkte über seine direkte Vertriebskraft, sowie über ein Netzwerk von ungefähr 100 Labor- und Vertriebspartnern an. Das Unternehmen hat eine Partnerschaftsvereinbarung mit BGI Genomics Co., Ltd. zur Entwicklung, Herstellung und Vermarktung von NGS-basierten genetischen Test-Assays; und Foundation Medicine, Inc. zur Entwicklung und Vermarktung personalisierter Überwachungs-Assays für zirkulierende Tumor-DNA. Das Unternehmen war früher als Gene Security Network, Inc. bekannt und änderte seinen Namen 2012 in Natera, Inc.. Natera, Inc. wurde 2003 gegründet und hat seinen Sitz in Austin, Texas.
Unternehmen & Branche
| Name | Natera, Inc. |
|---|---|
| Ticker | NTRA |
| CIK | 0001604821 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Medical - Diagnostics & Research |
| SIC | 8071 · Services-Medical Laboratories |
Wertpapier & Kennzahlen
| CUSIP | 632307104 |
|---|---|
| ISIN | US6323071042 |
| Typ | Common Stock |
| Marktkapitalisierung | 37,71 Mrd. USD |
| Beta | 1,56 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 13011 MCCALLEN PASS BUILDING A SUITE 100, 78753 AUSTIN, TX |
| Telefon | 650-249-9090 |
| EIN (IRS) | 01-0894487 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
Bewertung
| KBV (P/B) | 22,02 vs. 13,60 (2021) ▲ |
|---|---|
| KUV (P/S) | 16,35 vs. 14,21 (2021) ▲ |
| FCF-Rendite | 0,3 % vs. -4,2 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | -13,4 % vs. -74,8 % (2021) ▲ |
|---|---|
| Nettomarge | -9,0 % vs. -75,4 % (2021) ▲ |
| ROIC | -10,8 % vs. -44,9 % (2021) ▲ |
| Zinsdeckungsgrad | -76,2 vs. -56,4 (2021) ▼ |
| Forderungslaufzeit (DSO) | 47 T vs. 71 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 13,60 | 6,33 | 9,79 | 17,57 | 18,69 | 21,26 | |
| KUV (P/S) | 14,21 | 5,45 | 6,92 | 12,37 | 13,88 | 15,08 | |
| FCF-Rendite | -4,2 % | -10,7 % | -3,8 % | 0,3 % | 0,3 % | 0,3 % | |
| Qualität & Bilanz | |||||||
| Operative Marge | -74,8 % | -66,0 % | -41,2 % | -13,1 % | -13,4 % | -13,0 % | |
| Nettomarge | -75,4 % | -66,8 % | -40,2 % | -11,2 % | -9,0 % | -9,0 % | |
| ROIC | -44,9 % | -47,6 % | -36,0 % | -13,8 % | -10,8 % | -11,2 % | |
| Zinsdeckungsgrad | -56,4 | -58,1 | -35,3 | -20,8 | -76,2 | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
NTRA
Natera, Inc.
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
42,4
91 neu, 298 erhöht, -6477619K $ netto
Aktivist
11,4
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 228.41 | +19.4 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 214.20 | +27.3 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 26 Tagen @ 222.10 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 260.49 | EMA50: 238.52 | |
| MACD-Histogramm | Bärisch | 10 % | -0.768 | Bearisch | |
| RSI(14) | Neutral | 10 % | 63.6 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 68.6 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 32.5 | +DI: 27.7 / −DI: 16.1 | |
| Z-Score(60) | Bärisch | 5 % | 1.69 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 92.6 % | Hoch 283.80 / Tief 133.66 | |
| Bollinger(20,2σ) | Neutral | 5 % | 65.4 % | Upper 303.64 / Mid 258.86 / Lower 214.09 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.3761 | R²=0.70 / annualisiert +154.6 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-06 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.000 | 280,00 | -280.000,00 | -39,0% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -300 | 274,06 | -82.218,00 | -11,5% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -2.600 | 272,99 | -709.774,00 | -98,9% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -300 | 278,77 | -83.630,01 | -11,7% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -454 | 272,14 | -123.551,02 | -17,2% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -484 | 269,87 | -130.615,72 | -18,2% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -500 | 274,19 | -137.095,40 | -19,1% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.100 | 275,20 | -302.716,92 | -42,2% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.357 | 270,96 | -367.698,83 | -51,3% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.400 | 276,24 | -386.739,50 | -53,9% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.568 | 266,79 | -418.330,64 | -58,3% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.932 | 268,99 | -519.694,09 | -72,4% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.955 | 278,25 | -543.972,89 | -75,8% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -2.045 | 277,29 | -567.055,80 | -79,0% | |
| 2026-07-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -3.705 | 268,11 | -993.329,77 | -138,5% | |
| 2026-07-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -100 | 267,19 | -26.718,50 | -3,7% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -16.204 | 250,25 | -4.055.036,42 | -565,2% | |
| 2026-06-24 | ROSENMAN HERM | Director | Open Market Sale | -16.530 | 250,00 | -4.132.500,00 | -576,0% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -11.130 | 253,39 | -2.820.212,89 | -393,1% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -5.066 | 252,31 | -1.278.190,30 | -178,2% | |
| 2026-06-24 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.200 | 251,60 | -301.914,96 | -42,1% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -256 | 218,14 | -55.843,10 | -7,8% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -301 | 221,39 | -66.637,04 | -9,3% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -267 | 218,18 | -58.252,78 | -8,1% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -96 | 219,13 | -21.036,68 | -2,9% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -244 | 221,46 | -54.037,24 | -7,5% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -128 | 219,26 | -28.064,97 | -3,9% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -122 | 220,93 | -26.952,90 | -3,8% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -15 | 222,14 | -3.332,16 | -0,5% | |
| 2026-06-17 | Sheena Jonathan | Director | Open Market Sale | -71 | 220,46 | -15.652,89 | -2,2% | |
| 2026-06-16 | Chapman Rowan E | Director | Open Market Sale | -2.964 | 216,78 | -642.535,92 | -89,6% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -600 | 211,34 | -126.802,50 | -17,7% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -500 | 212,42 | -106.212,00 | -14,8% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -300 | 213,54 | -64.061,49 | -8,9% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.811 | 217,60 | -829.283,89 | -115,6% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.097 | 212,84 | -1.084.826,62 | -151,2% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -6.741 | 216,81 | -1.461.539,80 | -203,7% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.836 | 213,88 | -1.675.999,73 | -233,6% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -10.338 | 214,72 | -2.219.747,45 | -309,4% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -400 | 218,72 | -87.489,00 | -12,2% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -831 | 209,83 | -174.372,30 | -24,3% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.237 | 211,81 | -262.007,98 | -36,5% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.832 | 210,73 | -386.057,36 | -53,8% | |
| 2026-06-15 | Sheena Jonathan | Director | Open Market Sale | -1.750 | 210,29 | -368.011,18 | -51,3% | |
| 2026-06-15 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -11.877 | 215,91 | -2.564.338,13 | -357,5% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -12.142 | 212,27 | -2.577.401,77 | -359,3% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.536 | 209,50 | -531.280,08 | -74,1% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.133 | 218,17 | -465.356,61 | -64,9% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.605 | 219,36 | -352.069,75 | -49,1% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.267 | 210,30 | -687.047,81 | -95,8% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -3.161 | 215,38 | -680.815,23 | -94,9% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.957 | 211,61 | -625.736,98 | -87,2% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.276 | 217,32 | -929.278,28 | -129,5% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.034 | 213,43 | -1.074.398,57 | -149,8% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.707 | 214,35 | -1.223.301,16 | -170,5% | |
| 2026-06-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.182 | 216,51 | -1.554.959,02 | -216,8% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.016 | 216,06 | -651.646,31 | -90,8% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -4.694 | 217,30 | -1.020.023,10 | -142,2% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -3.174 | 218,11 | -692.276,06 | -96,5% | |
| 2026-06-05 | Marcus Gail Boxer | Director | Open Market Sale | -116 | 218,82 | -25.382,54 | -3,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.751 | 226,15 | -1.526.719,75 | -212,8% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.630 | 224,99 | -366.736,63 | -51,1% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.742 | 218,28 | -380.251,95 | -53,0% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.006 | 222,25 | -445.827,28 | -62,1% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.351 | 217,04 | -510.260,10 | -71,1% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.400 | 220,19 | -528.450,00 | -73,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.503 | 213,44 | -534.250,33 | -74,5% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.758 | 219,08 | -604.224,29 | -84,2% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -832 | 212,42 | -176.732,36 | -24,6% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.300 | 214,83 | -279.279,00 | -38,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.443 | 223,91 | -323.101,12 | -45,0% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.409 | 226,97 | -773.740,39 | -107,9% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -5.499 | 216,13 | -1.188.523,07 | -165,7% | |
| 2026-06-04 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -6.500 | 223,34 | -1.451.680,10 | -202,4% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -213 | 219,34 | -46.719,42 | -6,5% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.802 | 217,52 | -391.970,86 | -54,6% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -572 | 220,67 | -126.221,75 | -17,6% | |
| 2026-06-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -413 | 218,84 | -90.382,78 | -12,6% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -26.411 | 218,69 | -5.775.771,41 | -805,1% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -21.304 | 220,94 | -4.706.946,24 | -656,1% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -14.885 | 221,58 | -3.298.289,75 | -459,8% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -10.100 | 219,78 | -2.219.745,68 | -309,4% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.850 | 222,79 | -634.964,04 | -88,5% | |
| 2026-06-01 | BOTHA ROELOF | Director | Open Market Sale | -2.450 | 223,83 | -548.374,93 | -76,4% | |
| 2026-05-26 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -1.438 | 202,84 | -291.683,63 | -40,7% | |
| 2026-05-26 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.652 | 202,84 | -335.091,35 | -46,7% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -30 | 202,84 | -6.085,20 | -0,8% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -360 | 201,19 | -72.429,23 | -10,1% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -9 | 203,30 | -1.829,66 | -0,3% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -345 | 201,11 | -69.384,30 | -9,7% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -290 | 202,58 | -58.748,87 | -8,2% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -285 | 202,68 | -57.764,63 | -8,1% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -96 | 199,43 | -19.145,72 | -2,7% | |
| 2026-05-13 | Sheena Jonathan | Director | Open Market Sale | -85 | 199,52 | -16.958,98 | -2,4% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 205,43 | -41.086,00 | -5,7% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -700 | 208,13 | -145.690,02 | -20,3% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -900 | 207,24 | -186.516,99 | -26,0% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -1.150 | 210,35 | -241.896,75 | -33,7% | |
| 2026-05-08 | Sheena Jonathan | Director | Open Market Sale | -200 | 209,57 | -41.914,50 | -5,8% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.697 | 206,77 | -350.888,69 | -48,9% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -948 | 205,22 | -194.548,56 | -27,1% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.454 | 241,39 | -350.981,06 | -48,9% | |
| 2026-05-05 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.887 | 206,77 | -596.944,99 | -83,2% | |
| 2026-05-04 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -722 | 206,16 | -148.847,52 | -20,7% | |
| 2026-05-04 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -482 | 210,49 | -101.456,18 | -14,1% | |
| 2026-05-01 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -313 | 206,16 | -64.528,08 | -9,0% | |
| 2026-05-01 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -291 | 206,16 | -59.992,56 | -8,4% | |
| 2026-05-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -330 | 206,16 | -68.032,80 | -9,5% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -150 | 206,93 | -31.039,50 | -4,3% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -505 | 203,32 | -102.674,33 | -14,3% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -520 | 201,60 | -104.832,21 | -14,6% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -560 | 200,95 | -112.533,29 | -15,7% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -865 | 204,47 | -176.862,83 | -24,7% | |
| 2026-05-01 | Sheena Jonathan | Director | Open Market Sale | -107 | 206,16 | -22.059,12 | -3,1% | |
| 2026-05-01 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -902 | 206,16 | -185.956,32 | -25,9% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -405 | 206,16 | -83.494,80 | -11,6% | |
| 2026-05-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -400 | 205,31 | -82.123,00 | -11,4% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -2.266 | 196,22 | -444.623,42 | -62,0% | |
| 2026-04-29 | Sheena Jonathan | Director | Open Market Sale | -805 | 196,99 | -158.575,02 | -22,1% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.000 | 193,78 | -193.779,00 | -27,0% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -200 | 197,26 | -39.452,00 | -5,5% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -300 | 190,12 | -57.034,50 | -8,0% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -500 | 192,13 | -96.064,30 | -13,4% | |
| 2026-04-29 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.070 | 194,82 | -208.459,54 | -29,1% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -997 | 203,75 | -203.138,75 | -28,3% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -21,9% | |
| 2026-04-27 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -917 | 204,39 | -187.425,63 | -26,1% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -771 | 203,75 | -157.091,25 | -21,9% | |
| 2026-04-27 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.222 | 204,39 | -249.764,58 | -34,8% | |
| 2026-04-27 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.185 | 204,39 | -242.202,15 | -33,8% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.272 | 203,75 | -462.920,00 | -64,5% | |
| 2026-04-27 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -3.566 | 204,39 | -728.854,74 | -101,6% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -188 | 204,39 | -38.425,32 | -5,4% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -988 | 204,39 | -201.937,32 | -28,1% | |
| 2026-04-27 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -873 | 203,75 | -177.873,75 | -24,8% | |
| 2026-04-27 | Sheena Jonathan | Director | Open Market Sale | -285 | 203,75 | -58.068,75 | -8,1% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,66 | -149.748,00 | -20,9% | |
| 2026-04-17 | Sheena Jonathan | Director | Open Market Sale | -750 | 199,59 | -149.692,95 | -20,9% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.200 | 203,83 | -244.590,96 | -34,1% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.778 | 202,01 | -359.167,02 | -50,1% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.909 | 205,00 | -391.349,96 | -54,6% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -3.213 | 203,07 | -652.470,34 | -91,0% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -952 | 203,31 | -193.551,69 | -27,0% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.000 | 202,36 | -202.363,80 | -28,2% | |
| 2026-04-01 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.048 | 201,32 | -210.983,99 | -29,4% | |
| 2026-04-01 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -300 | 200,79 | -60.236,04 | -8,4% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -371 | 200,97 | -74.561,35 | -10,4% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -239 | 198,85 | -47.526,32 | -6,6% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 199,88 | -46.971,10 | -6,5% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -235 | 198,49 | -46.644,19 | -6,5% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -140 | 199,82 | -27.975,40 | -3,9% | |
| 2026-03-20 | Sheena Jonathan | Director | Open Market Sale | -280 | 200,90 | -56.252,64 | -7,8% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -956 | 197,84 | -189.135,14 | -26,4% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -300 | 196,27 | -58.880,01 | -8,2% | |
| 2026-03-18 | Sheena Jonathan | Director | Open Market Sale | -1.814 | 198,65 | -360.355,09 | -50,2% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -24.814 | 196,23 | -4.869.290,92 | -678,7% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -100 | 190,07 | -19.007,08 | -2,6% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -254 | 198,02 | -50.297,18 | -7,0% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -300 | 190,68 | -57.203,07 | -8,0% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -900 | 192,43 | -173.185,02 | -24,1% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.300 | 194,17 | -446.592,61 | -62,3% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.875 | 195,42 | -952.695,90 | -132,8% | |
| 2026-03-16 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -16.457 | 197,22 | -3.245.611,69 | -452,4% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -13.883 | 190,46 | -2.644.206,16 | -368,6% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.476 | 188,54 | -4.049.190,27 | -564,4% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -1.100 | 191,22 | -210.344,97 | -29,3% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -17.037 | 187,63 | -3.196.631,87 | -445,6% | |
| 2026-03-13 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -21.504 | 189,50 | -4.075.005,85 | -568,0% | |
| 2026-03-13 | Chapman Rowan E | Director | Open Market Sale | -122 | 191,38 | -23.348,36 | -3,3% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -2.886 | 189,64 | -547.306,81 | -76,3% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -100 | 195,32 | -19.532,00 | -2,7% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -7.043 | 193,58 | -1.363.388,87 | -190,0% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -8.579 | 192,79 | -1.653.957,42 | -230,6% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -8.091 | 186,75 | -1.510.989,40 | -210,6% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -5.809 | 187,52 | -1.089.299,61 | -151,8% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -4.082 | 194,57 | -794.218,00 | -110,7% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -22.063 | 190,53 | -4.203.720,75 | -586,0% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -9.896 | 191,55 | -1.895.594,63 | -264,2% | |
| 2026-03-12 | Rabinowitz Matthew | Director, Officer, EXECUTIVE CHAIRMAN | Open Market Sale | -6.451 | 188,52 | -1.216.111,56 | -169,5% | |
| 2026-03-10 | Sheena Jonathan | Director | Open Market Sale | -127 | 204,13 | -25.924,85 | -3,6% | |
| 2026-03-10 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -915 | 204,13 | -186.781,42 | -26,0% | |
| 2026-03-10 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.745 | 204,13 | -356.211,56 | -49,7% | |
| 2026-03-10 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -5.623 | 204,13 | -1.147.838,17 | -160,0% | |
| 2026-03-10 | Fesko John | Officer, PRESIDENT, CHIEF BUS. OFFICER | Open Market Sale | -707 | 204,13 | -144.321,82 | -20,1% | |
| 2026-03-10 | Brophy Michael Burkes | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -785 | 204,13 | -160.244,17 | -22,3% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -2.900 | 194,77 | -564.832,42 | -78,7% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -400 | 193,73 | -77.491,16 | -10,8% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.500 | 196,94 | -295.406,10 | -41,2% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.600 | 195,80 | -313.272,64 | -43,7% | |
| 2026-03-06 | RABINOWITZ DANIEL | Officer, SEC. AND CHIEF LEGAL OFFICER | Open Market Sale | -1.998 | 198,04 | -395.693,51 | -55,2% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -100 | 201,20 | -20.120,00 | -2,8% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -931 | 198,83 | -185.114,27 | -25,8% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -1.594 | 200,11 | -318.971,04 | -44,5% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -470 | 198,50 | -93.292,93 | -13,0% | |
| 2026-03-02 | Moshkevich Solomon | Officer, PRESIDENT, CLINICALDIAGNOSTICS | Open Market Sale | -475 | 200,97 | -95.459,75 | -13,3% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -100 | 202,85 | -20.285,00 | -2,8% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -365 | 201,18 | -73.429,50 | -10,2% | |
| 2026-03-02 | Sheena Jonathan | Director | Open Market Sale | -2.400 | 200,42 | -481.012,08 | -67,0% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -1.122 | 199,17 | -223.472,89 | -31,2% | |
| 2026-03-02 | Chapman Steven Leonard | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -2.463 | 200,24 | -493.192,60 | -68,7% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 10.677.338 | 0 | 10.677.338 | 2.135.360.953 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 0 | 6.008.496 | 1.201.639.115 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | 0 | 4.768.593 | 953.670.913 | Neu | +100,0% | |
| STATE STREET CORP | 3.417.472 | 0 | 3.417.472 | 683.460.225 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3.207.366 | 0 | 3.207.366 | 641.441.126 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.775.928 | 0 | 2.775.928 | 553.818.995 | Neu | +100,0% | |
| FMR LLC | 2.554.254 | 0 | 2.554.254 | 510.825.126 | Neu | +100,0% | |
| COATUE MANAGEMENT LLC | 2.541.842 | 0 | 2.541.842 | 508.342.981 | Neu | +100,0% | |
| Castle Hook Partners LP | 2.529.810 | 0 | 2.529.810 | 505.936.702 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.485.325 | 0 | 2.485.325 | 497.040.120 | Neu | +100,0% | |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | 0 | 2.273.991 | 442.564.045 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.040.106 | 0 | 2.040.106 | 407.990.494 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 1.756.472 | 0 | 1.756.472 | 351.276.835 | Neu | +100,0% | |
| Sofinnova Investments, Inc. | 1.550.280 | 0 | 1.550.280 | 310.040.497 | Neu | +100,0% | |
| Capital World Investors | 1.467.975 | 0 | 1.467.975 | 293.580.320 | Neu | +100,0% | |
| MORGAN STANLEY | 1.354.335 | 0 | 1.354.335 | 270.853.971 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 1.250.000 | 0 | 1.250.000 | 249.987.500 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.191.732 | 0 | 1.191.732 | 238.334.483 | Neu | +100,0% | |
| MAVERICK CAPITAL LTD | 1.171.633 | 0 | 1.171.633 | 234.314.884 | Neu | +100,0% | |
| FEDERATED HERMES, INC. | 1.090.030 | 0 | 1.090.030 | 217.995.100 | Neu | +100,0% | |
| Clearbridge Investments, LLC | 893.322 | 0 | 893.322 | 178.655.567 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 822.831 | 0 | 822.831 | 164.557.971 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 788.445 | 0 | 788.445 | 157.681.116 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 755.275 | 0 | 755.275 | 151.047.391 | Neu | +100,0% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 754.729 | 0 | 754.729 | 150.938.268 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 752.936 | 0 | 752.936 | 150.579.670 | Neu | +100,0% | |
| PointState Capital LP | 739.879 | 0 | 739.879 | 147.968.401 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 733.669 | 0 | 733.669 | 146.726.383 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 712.748 | 0 | 712.748 | 142.542.473 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 692.368 | 0 | 692.368 | 138.466.676 | Neu | +100,0% | |
| ARK Investment Management LLC | 684.255 | 0 | 684.255 | 136.844.067 | Neu | +100,0% | |
| MAPLELANE CAPITAL, LLC | 474.862 | 0 | 474.862 | 135.793.211 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 631.338 | 0 | 631.338 | 126.261.287 | Neu | +100,0% | |
| Chevy Chase Trust Holdings, LLC | 587.030 | 0 | 587.030 | 117.400.131 | Neu | +100,0% | |
| RAYMOND JAMES FINANCIAL INC | 591.043 | 0 | 591.043 | 112.321.645 | Neu | +100,0% | |
| FIRST TRUST ADVISORS LP | 528.798 | 0 | 528.798 | 105.754.264 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 515.238 | 0 | 515.238 | 103.042.447 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 499.977 | 0 | 499.977 | 99.990.400 | Neu | +100,0% | |
| Legal & General Group Plc | 498.141 | 0 | 498.141 | 99.623.224 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 496.904 | 0 | 496.904 | 99.375.831 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 491.336 | 0 | 491.336 | 98.262.287 | Neu | +100,0% | |
| AGF MANAGEMENT LTD | 491.262 | 0 | 491.262 | 98.247.487 | Neu | +100,0% | |
| Nuveen, LLC | 474.608 | 0 | 474.608 | 94.916.853 | Neu | +100,0% | |
| Allspring Global Investments Holdings, LLC | 463.477 | 0 | 463.477 | 94.183.161 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 444.199 | 0 | 444.199 | 88.835.358 | Neu | +100,0% | |
| Amova Asset Management Americas, Inc. | 423.424 | 0 | 423.424 | 84.684.800 | Neu | +100,0% | |
| UBS Group AG | 422.899 | 0 | 422.899 | 84.575.571 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 409.151 | 0 | 409.151 | 81.826.142 | Neu | +100,0% | |
| Robeco Institutional Asset Management B.V. | 405.713 | 0 | 405.713 | 81.138.543 | Neu | +100,0% | |
| Swiss National Bank | 385.600 | 0 | 385.600 | 77.116.144 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| Assenagon Asset Management S.A. | 250.869 | 60.535 | +314,4% | 68.098.390 | 45,16 | 100 % | 17 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 55.959 | 51.147 | +9,4% | 13.651.708 | 9,05 | 3 % | 11 Q |
| Systrade AG | 50.000 | 50.000 | 0,0% | 13.572.500 | 9,00 | 100 % | 3 Q |
| Swedbank AB | 45.534 | 45.534 | 0,0% | 12.360.205 | 8,20 | 100 % | 8 Q |
| DAVENPORT & Co LLC | 22.899 | 25.011 | -8,4% | 6.215.934 | 4,12 | 100 % | 3 Q |
| QRG CAPITAL MANAGEMENT, INC. | 19.488 | 14.691 | +32,7% | 5.289.969 | 3,51 | 100 % | 8 Q |
| SALEM INVESTMENT COUNSELORS INC | 16.530 | 16.530 | 0,0% | 4.487.069 | 2,98 | 57 % | 9 Q |
| PensionDanmark Pensionsforsikringsaktieselskab | 13.770 | 12.540 | +9,8% | 3.737.867 | 2,48 | 0 % | 3 Q |
| Teamwork Financial Advisors, LLC | 10.815 | 0 | +100,0% | 2.935.732 | 1,95 | 0 % | 1 Q |
| INDEPENDENT FINANCIAL GROUP, LLC | 9.057 | 4.909 | +84,5% | 2.458.522 | 1,63 | 0 % | 3 Q |
| NorthCrest Asset Manangement, LLC | 5.160 | 4.692 | +10,0% | 1.454.346 | 0,96 | 2 % | 5 Q |
| Roxbury Financial LLC | 5.024 | 900 | +458,2% | 1.363.765 | 0,90 | 0 % | 7 Q |
| Octavia Wealth Advisors, LLC | 4.488 | 4.549 | -1,3% | 1.218.268 | 0,81 | 0 % | 3 Q |
| HARBOR INVESTMENT ADVISORY, LLC | 4.389 | 3.576 | +22,7% | 1.191.394 | 0,79 | 100 % | 9 Q |
| TEMA ETFS LLC | 4.238 | 4.974 | -14,8% | 1.150.405 | 0,76 | 100 % | 2 Q |
| WADDELL & ASSOCIATES, LLC | 3.827 | 3.767 | +1,6% | 1.038.839 | 0,69 | 0 % | 5 Q |
| Central Pacific Bank - Trust Division | 3.473 | 3.473 | 0,0% | 942.746 | 0,63 | 0 % | 10 Q |
| E. Ohman J:or Asset Management AB | 3.232 | 27.395 | -88,2% | 877.326 | 0,58 | 100 % | 14 Q |
| TLWM | 2.973 | 2.973 | 0,0% | 807.022 | 0,54 | 0 % | 10 Q |
| Avior Wealth Management, LLC | 2.780 | 2.781 | 0,0% | 754.631 | 0,50 | 0 % | 10 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 60 | 0,8 | 151 |
| 31.03.2026 | ✓ | 745 | 140,1 | 23.814 |
| 31.12.2025 | ✓ | 763 | 137,4 | 27.289 |
| 30.09.2025 | ✓ | 680 | 149,3 | 20.742 |
| 30.06.2025 | ✓ | 641 | 132,2 | 18.942 |
| 31.03.2025 | ✓ | 590 | 134,3 | 16.332 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 6.008.496 | 1.201.639.115 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3.207.366 | 641.441.126 |
| MAPLELANE CAPITAL, LLC | 339.000 | 67.796.611 |
| CIBC Bancorp USA Inc. | 157.124 | 31.417.629 |
| Avala Global LP | 152.100 | 30.418.479 |
| SEB Asset Management AB | 85.074 | 17.013.934 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 69.767 | 13.952.702 |
| PFM Health Sciences, LP | 60.004 | 12.000.200 |
| MARSHALL WACE, LLP | 53.702 | 10.739.863 |
| Tredje AP-fonden | 46.612 | 9.321.934 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 12.184.876 | 1.312.887 | +12.1 % | 2.436.855 |
| FMR LLC | 2.554.254 | 1.078.266 | +73.1 % | 510.825.126 |
| T. Rowe Price Investment Management, Inc. | 1.130.820 | 632.461 | +126.9 % | 226.153 |
| Duquesne Family Office LLC | 3.063.606 | 552.249 | +22.0 % | 612.691 |
| JPMORGAN CHASE & CO | 13.386.667 | 532.333 | +4.1 % | 2.501.165.314 |
| Castle Hook Partners LP | 2.529.810 | 361.941 | +16.7 % | 505.936.702 |
| Point72 Asset Management, L.P. | 444.199 | 318.887 | +254.5 % | 88.835.358 |
| Man Group plc | 265.440 | 240.571 | +967.4 % | 53.085.345 |
| MAVERICK CAPITAL LTD | 1.171.633 | 227.605 | +24.1 % | 234.314.884 |
| FIRST TRUST ADVISORS LP | 528.798 | 209.056 | +65.4 % | 105.754.264 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | 284.338 | -341.574 | -54.6 % | 56.864.757 |
| AQR CAPITAL MANAGEMENT LLC | 2.273.991 | -325.308 | -12.5 % | 442.564.045 |
| RTW INVESTMENTS, LP | 1.250.000 | -250.000 | -16.7 % | 249.987.500 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 294.347 | -227.403 | -43.6 % | 58.866.433 |
| TWO SIGMA INVESTMENTS, LP | 40.200 | -227.040 | -85.0 % | 8.039.598 |
| PANAGORA ASSET MANAGEMENT INC | 172.730 | -220.690 | -56.1 % | 34.544.273 |
| Kinetic Partners Management, LP | 60.800 | -212.500 | -77.8 % | 12.159.392 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.768.593 | -207.732 | -4.2 % | 953.670.913 |
| BlackRock, Inc. | 10.677.338 | -182.103 | -1.7 % | 2.135.360.953 |
| BANK OF AMERICA CORP /DE/ | 733.669 | -141.704 | -16.2 % | 146.726.383 |
Zusätzlich aktuell von 300 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,08 % | 7.205.939 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -9,13 pp | |
| 17.02.2026 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.872.702 | -1,10 pp | |
| 23.01.2026 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 9,10 % | 12.825.640 | +1,40 pp | |
| 14.08.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 8,90 % | 12.191.814 | +1,10 pp | |
| 22.07.2025 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 7,70 % | 10.594.256 | +2,70 pp | |
| 14.05.2025 | T. Rowe Price Associates, Inc. | Passiv (13G/A) | 7,80 % | 10.554.721 | +2,70 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,60 % | 7.565.936 | Neu | |
| 14.02.2025 | T. Rowe Price Associates, Inc. | Passiv (13G) | 5,10 % | 6.742.428 | Neu | |
| 10.02.2025 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,00 % | 6.668.519 | +0,70 pp | |
| 14.11.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 3,20 % | 4.011.957 | -2,70 pp | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | 0,00 pp | |
| 22.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 8.237.984 | +1,50 pp | |
| 07.06.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 4,30 % | 5.335.516 | -2,30 pp | |
| 14.02.2024 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 5,90 % | 7.076.157 | -2,30 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,13 % | 10.971.895 | +0,12 pp | |
| 31.01.2024 | . BlackRock, Inc. | Passiv (13G) | 5,20 % | 6.305.838 | +0,30 pp | |
| 23.01.2024 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 6,60 % | 7.964.473 | +1,00 pp | |
| 06.04.2023 | . BlackRock, Inc. | Passiv (13G/A) | 4,90 % | 5.509.188 | -0,20 pp | |
| 14.02.2023 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 8,20 % | 8.972.721 | +1,00 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,01 % | 9.945.514 | +0,78 pp | |
| 03.02.2023 | . BlackRock, Inc. | Passiv (13G) | 5,10 % | 5.566.743 | +0,20 pp | |
| 23.01.2023 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 5,60 % | 6.211.632 | +0,30 pp | |
| 09.06.2022 | . BlackRock, Inc. | Passiv (13G) | 4,90 % | 4.706.415 | -2,50 pp | |
| 14.02.2022 | Alger Associates, Inc. 13-3017981 | Passiv (13G/A) | 7,20 % | 6.805.028 | -0,08 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,23 % | 7.785.953 | -0,44 pp | |
| 03.02.2022 | . BlackRock, Inc. | Passiv (13G/A) | 7,40 % | 7.010.757 | +0,10 pp | |
| 24.01.2022 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,30 % | 5.025.967 | Neu |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 22.09.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 22.08.2025 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
| 20.11.2024 | Josh Gottheimer | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 696.644.000 $ | -85.091.000 $ | -0,60 $ | 2.614.398.000 $ | 1.774.018.000 $ |
| 2025-12-31 | 10-K | 2.306.113.000 $ | -208.160.000 $ | -1,52 $ | 2.398.344.000 $ | 1.712.413.000 $ |
| 2025-09-30 | 10-Q | 592.183.000 $ | -87.544.000 $ | -0,64 $ | 1.821.482.000 $ | 1.252.188.000 $ |
| 2025-06-30 | 10-Q | 546.600.000 $ | -100.938.000 $ | -0,74 $ | 1.757.066.000 $ | 1.246.182.000 $ |
| 2025-03-31 | 10-Q | 501.830.000 $ | -66.936.000 $ | -0,50 $ | 1.732.366.000 $ | 1.239.675.000 $ |
| 2024-12-31 | 10-K | 1.696.911.000 $ | -190.426.000 $ | -1,53 $ | 1.660.735.000 $ | 1.195.420.000 $ |
| 2024-09-30 | 10-Q | 439.758.000 $ | -31.592.000 $ | -0,26 $ | 1.590.947.000 $ | 878.525.000 $ |
| 2024-06-30 | 10-Q | 413.351.000 $ | -37.464.000 $ | -0,30 $ | 1.516.989.000 $ | 836.520.000 $ |
| 2024-03-31 | 10-Q | 367.741.000 $ | -67.599.000 $ | -0,56 $ | 1.468.205.000 $ | 794.111.000 $ |
| 2023-12-31 | 10-K | 1.082.571.000 $ | -434.801.000 $ | -3,78 $ | 1.441.699.000 $ | 765.327.000 $ |
| 2023-09-30 | 10-Q | 268.306.000 $ | -109.030.000 $ | -0,95 $ | 1.446.520.000 $ | 784.658.000 $ |
| 2023-06-30 | 10-Q | 261.404.000 $ | -110.803.000 $ | -0,97 $ | 1.247.893.000 $ | 596.147.000 $ |
| 2023-03-31 | 10-Q | 241.756.000 $ | -136.937.000 $ | -1,23 $ | 1.318.880.000 $ | 650.573.000 $ |
| 2022-12-31 | 10-K | 820.222.000 $ | -547.799.000 $ | -5,57 $ | 1.394.474.000 $ | 705.744.000 $ |
| 2022-09-30 | 10-Q | 210.637.000 $ | -121.480.000 $ | -1,25 $ | 1.009.112.000 $ | 361.621.000 $ |
| 2022-06-30 | 10-Q | 198.200.000 $ | -145.151.000 $ | -1,50 $ | 1.066.976.000 $ | 444.582.000 $ |
| 2022-03-31 | 10-Q | 194.133.000 $ | -138.595.000 $ | -1,45 $ | 1.144.664.000 $ | 542.335.000 $ |
| 2021-12-31 | 10-K | 625.486.000 $ | -471.716.000 $ | -5,21 $ | 1.236.487.000 $ | 653.304.000 $ |
| 2021-09-30 | 10-Q | 158.116.000 $ | -151.273.000 $ | -1,63 $ | 1.311.374.000 $ | 759.017.000 $ |
| 2021-06-30 | 10-Q | 142.026.000 $ | -116.026.000 $ | -1,32 $ | 849.956.000 $ | 299.110.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 2,3 Mrd. | 1,7 Mrd. | 1,1 Mrd. | 797,3 Mio. | 580,1 Mio. | 99,6 % | +36,2% | |
| Licensing And Other | 10,3 Mio. | 11,8 Mio. | 14,0 Mio. | 22,9 Mio. | 45,4 Mio. | 0,4 % | -13,0% |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 2,3 Mrd. | 1,7 Mrd. | 1,0 Mrd. | 785,8 Mio. | 590,9 Mio. | 98,2 % | +36,6% | |
| Europe Middle East India And Africa | 24,5 Mio. | 23,9 Mio. | 22,8 Mio. | 16,6 Mio. | 20,4 Mio. | 1,1 % | +2,5% | |
| Americas Excluding Us | 9,4 Mio. | 6,6 Mio. | 4,9 Mio. | 3,7 Mio. | 4,0 Mio. | 0,4 % | +41,3% | |
| Other Geographic Areas | 8,0 Mio. | 8,7 Mio. | 7,2 Mio. | 14,0 Mio. | 10,1 Mio. | 0,3 % | -7,5% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 696,6 Mio. USD | -0,60 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 592,2 Mio. USD | -0,64 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 546,6 Mio. USD | -0,74 |
| Q1 2025 | 31.03.2025 | 09.05.2025 | 501,8 Mio. USD | -0,50 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | 439,8 Mio. USD | -0,26 |
| Q2 2024 | 30.06.2024 | 09.08.2024 | 413,4 Mio. USD | -0,30 |
| Q1 2024 | 31.03.2024 | 10.05.2024 | 367,7 Mio. USD | -0,56 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | 268,3 Mio. USD | -0,95 |
| Q2 2023 | 30.06.2023 | 04.08.2023 | 261,4 Mio. USD | -0,97 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | 31.03.2026 | 38 Tage | SEC » |
| 27.02.2026 | 10-K | 31.12.2025 | 58 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 09.05.2025 | 10-Q | 31.03.2025 | 39 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 10.05.2023 | 10-Q | 31.03.2023 | 40 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 07.09.2023 | Kapitalerhöhung | – | SEC » |
| 16.11.2022 | Kapitalerhöhung | – | SEC » |
| 22.07.2021 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | Form | |
|---|---|---|---|
| 23.04.2026 | HV-Einladung | DEFA14A | SEC » |
| 23.04.2026 | HV-Einladung | DEF 14A | SEC » |
| 24.04.2025 | HV-Einladung | DEFA14A | SEC » |
| 24.04.2025 | HV-Einladung | DEF 14A | SEC » |
| 05.06.2024 | HV-Einladung | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | DEFA14A | SEC » |
| 24.04.2024 | HV-Einladung | DEF 14A | SEC » |
| 20.04.2023 | HV-Einladung | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | DEF 14A | SEC » |
| 13.04.2022 | HV-Einladung | DEFA14A | SEC » |
| 13.04.2022 | HV-Einladung | DEF 14A | SEC » |
| 13.04.2021 | HV-Einladung | DEFA14A | SEC » |
| 13.04.2021 | HV-Einladung | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termine und Vergütung stehen im Dokument (SEC-Link).
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (06.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (05.06.2026)
HOCH Abgang Schlüsselpersonen (06.07.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (16.06.2026)
HOCH Abgang Schlüsselpersonen (05.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 06.07.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.04.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 15.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 06.07.2026 | Personalwechsel | 0,05 | 28 | Boardmitglied Monica Bertagnolli tritt zum 1. Juli 2026 zurück, um ihre neue Position bei der National Academy of Medicine anzunehmen. | SEC |
| 16.06.2026 | HV-Abstimmung | 0,00 | 38 | Aktionäre von Natera billigten am 11. Juni 2026 auf ihrer Jahresversammlung fünf Vorschläge ab, einschließlich einer Änderung des Equity-Inc… 🔒 | SEC |
| 16.06.2026 | Personalwechsel | 0,15 | 30 | Thomas Lynch wurde zum Boardmitglied ernannt. Das Board der Natera, Inc. wurde von elf auf zwölf Mitglieder erweitert (effektiv 2. Juni 2026… 🔒 | SEC |
| 05.06.2026 | Personalwechsel | 0,15 | 22 | Natera erweitert seinen Vorstand von 11 auf 12 Mitglieder und ernennt Thomas Lynch ab 2. Juni 2026 als neues Vorstandsmitglied der Klasse I. | SEC |
| 07.05.2026 | Quartalszahlen | 0,00 | 60 | Natera veröffentlichte Q1-2026-Ergebnisse (bis 31. März 2026) per Pressemitteilung und Präsentation. | SEC |
| 01.04.2026 | Personalwechsel | 0,05 | 30 | Natera ernennt Eric Rubin zum Vorstandsmitglied und erweitert die Boardgröße von zehn auf elf Mitglieder. | SEC |
| 26.02.2026 | Quartalszahlen | 0,00 | 70 | Natera veröffentlichte Pressemitteilung und Investorenpräsentation zu Q4- und Jahresergebnissen 2025 (zum 31. Dezember 2025). | SEC |
| 12.01.2026 | Quartalszahlen | 0,00 | 60 | Natera gab am 11. Januar 2026 vorläufige Geschäftsergebnisse für Q4 und Geschäftsjahr 2025 bekannt. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 121 | 272,31 | 32.950 |
| 2026-06-25 | 1.370 | 259,97 | 356.159 |
| 2026-06-22 | 500 | 231,41 | 115.705 |
| 2026-06-18 | 22 | 226,44 | 4.982 |
| 2026-06-15 | 3.539 | 212,07 | 750.516 |
| 2026-06-12 | 15.326 | 219,23 | 3.359.919 |
| 2026-06-10 | 949 | 222,82 | 211.456 |
| 2026-06-09 | 104 | 213,47 | 22.201 |
| 2026-06-04 | 5.154 | 211,85 | 1.091.875 |
| 2026-06-03 | 5 | 212,73 | 1.064 |
| 2026-06-02 | 2 | 218,81 | 438 |
| 2026-05-29 | 12.831 | 213,94 | 2.745.064 |
| 2026-04-24 | 571 | 201,14 | 114.851 |
| 2026-04-21 | 516 | 207,74 | 107.194 |
| 2026-04-17 | 967 | 196,11 | 189.638 |
| 2026-04-15 | 622 | 214,64 | 133.506 |
| 2026-04-08 | 188 | 209,27 | 39.343 |
| 2026-04-06 | 21 | 207,98 | 4.368 |
| 2026-03-31 | 83.324 | 186,84 | 15.568.256 |
| 2026-03-24 | 6 | 200,09 | 1.201 |
| 2026-03-11 | 834 | 198,95 | 165.924 |
| 2026-03-02 | 7.751 | 208,04 | 1.612.518 |
| 2026-02-10 | 12 | 210,58 | 2.527 |
| 2026-01-29 | 3 | 235,93 | 708 |
| 2026-01-21 | 86 | 234,85 | 20.197 |